KYV-201

About Kyverna Therapeutics

Kyverna Therapeutics is advancing a new class of cellular therapies designed to reset the immune system in patients with severe autoimmune diseases. The company leverages its proprietary synthetic biology platform to engineer CD19-targeting CAR T-cells, with its lead asset KYV-101 showing promising early clinical data. Following a successful IPO in February 2024, Kyverna is rapidly advancing multiple clinical programs while expanding its pipeline into additional autoimmune indications. The company represents a pioneering force in applying cell therapy beyond oncology to address significant unmet needs in autoimmunity.

Therapeutic Areas